About the Company
denali therapeutics inc. (“denali”) is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including alzheimer’s disease, parkinson’s disease, als and others. denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. denali is rigorously pursuing a science-driven approach to translational medicine and clinical development. founding investors include fidelity biosciences, arch venture partners, flagship ventures and the alaska permanent fund (represented by crestline investors).
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $DNLI News
Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report?
A month has gone by since the last earnings report for Denali Therapeutics Inc. (DNLI). Shares have added about 2.8% in that time frame, underperforming the S&P 500. Will the recent positive trend ...
Denali Therapeutics gets grant for proteins for treating sanfilippo syndrome A
Discover how Denali Therapeutics' patented proteins can revolutionize the treatment of Sanfilippo syndrome A by crossing the blood-brain barrier with enhanced efficiency. Explore the groundbreaking ...
Denali's (DNLI) Q4 Earnings Miss, Pipeline in Focus, Stock Up
Denali Therapeutics DNLI incurred a loss of 86 cents ... A better-ranked stock from the drug/biotech industry is Puma ...
4 Analysts Assess Denali Therapeutics: What You Need To Know
Unveiling the Story Behind Denali Therapeutics Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease.
Denali Therapeutics Announces $500 million Private Placement Equity Financing
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to ...
Denali Therapeutics Inc DNLI
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to ...
Denali Therapeutics Inc (DNLI) Reports Full Year and Q4 2023 Financial Results
Warning! GuruFocus has detected 2 Warning Sign with DNLI. Denali Therapeutics Inc (NASDAQ:DNLI) released its 8-K filing on February 27, 2024, detailing its financial results for the fourth quarter ...
Denali Therapeutics Announces $500 million Private Placement Equity Financing
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to ...
Denali Therapeutics Inc.: Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to ...
Loading the latest forecasts...